MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Lamictal 50mg tablets (GlaxoSmithKline UK Ltd) and Lamotrigine 50mg tablets (Milpharm Ltd).

Stability Notes

Unsuitable for MCA as dispersible tablets.

Provenance

This compatibility recommendation is derived from Lamictal 5mg dispersible tablets (GlaxoSmithKline UK Ltd).

Stability Notes

Unsuitable for MCA as dispersible tablets.

Provenance

This compatibility recommendation is derived from Lamictal 5mg dispersible tablets (GlaxoSmithKline UK Ltd).

Stability Notes

Unsuitable for MCA as dispersible tablets.

Provenance

This compatibility recommendation is derived from Lamictal 5mg dispersible tablets (GlaxoSmithKline UK Ltd).

Stability Notes

Unsuitable for MCA as dispersible tablets.

Provenance

This compatibility recommendation is derived from Lamictal 5mg dispersible tablets (GlaxoSmithKline UK Ltd).

Stability Notes

This medicinal product does not require any special storage conditions.

Provenance

This compatibility recommendation is derived from Diamicron 30mg MR tablets (Servier Laboratories Ltd).

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Lansoprazole 15mg gastro-resistant capsules (Accord Healthcare Ltd).

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Lansoprazole 15mg gastro-resistant capsules (Accord Healthcare Ltd).

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Lansoprazole 15mg gastro-resistant capsules (Accord Healthcare Ltd).

Stability Notes

Protect from moisture.

Provenance

This compatibility recommendation is derived from Lansoprazole 15mg gastro-resistant capsules (Accord Healthcare Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.